Supplemental Figure 1A

Cincinnati <u>Children's</u>

Guideline Highlights

Management of Inflammatory Bowel Disease (IBD)

Target Population: Children 0 to 22 years of age diagnosed with IBD (either Crohn's Disease (CD) or Ulcerative Colitis (UC)). **Guideline Recommendations**

Prior to Treatment

- Use a **physician global assessment** (PGA) to determine disease severity (quiescent, mild, and moderate/severe). 1.
- 2. Consider use of: Pediatric Crohn's Disease Activity Index (PCDAI) or Pediatric Ulcerative Colitis Activity Index (PUCAI)
- 3. Immunizations be given in accordance with the American Academy of Pediatrics and American Academy of Family Physicians recommendations Obtain

6-MP / Azathioprine(AZA) with or without prednisone (also see the algorithm in Appendix #6 & Guideline)

- 4. Indications: a. induction of remission in children with moderate to severe (per
 - physician global assessment) CD AND o TPMT genotype consistent with TPMT activity present o CBC, ALT, amylase, lipase baseline levels within appropriate limits
 - b. induction of remission in children with moderate to severe CD or UC AND
 - not initially given 6-MP or AZA to induce remission, AND
 - Contraindications: TPMT genotype that is consistent with absent TPMT activity; abnormal WBC, ALT, amylase, or lipase levels
- Safety Monitoring: Obtain baseline levels of: WBC, ALT, amylase, lipase; WBC & ALT at 2, 4, 8 and 12 weeks after initiation of 6-MP or AZA (& q 6. 3 months there after) that may influence dosing changes; Do Not give live virus vaccines
- Dosing: Use TPMT level or (genotype) to determine dosing as recommended in guideline. Ranges include 6-MP 0.75 to 1.5 mg / kg / day P.O. or 7. azathioprine (AZA) 1 to 2.5 mg / kg / day P.O. Prednisone should be discontinued within 3 months of being initiated.
- 8. Efficacy Monitoring: Assess if have achieved adequate clinical response to 6-MP or AZA (defined as a decreased physician global assessment to the quiescent or mild level); if not, use 6-TG levels to further adjust dosing / continued use
- 9 Adjunct Therapy / Other Treatment-Related Interventions / Education: educate patients and families regarding signs and symptoms of pancreatitis and to report any signs or symptoms of possible infections

Methotrexate (MTX) (also see the algorithm in Appendix #7 & Guideline)

10. Indications:

5.

a. induction of remission as an alternative to Infliximab in children with moderate / severe CD AND

- o received more than one course of steroids in one year, or
- o not achieved remission after one month of prednisone alone, or
- · did not respond or were intolerant 6-MP/AZA to induce remission AND
- o not tapered off prednisone after three months

• that are steroid-dependent/refractory, defined as:

o received more than one course of steroids in one year, or

o not tapered off prednisone after three months OR

c. maintenance therapy in children with moderate/severe CD/UC

who have failed or cannot tolerate 5-aminosalcylates

o not achieved remission after one month of prednisone alone, or

b. maintenance therapy in children with CD


- that are steroid-dependent/refractory, defined as:
- 11. Contraindications: pregnant females; children with CD with already abnormal liver-associated chemistries
- Safety Monitoring: Prior to MTX initiation: females of child bearing age be tested for pregnancy and be proactive in pregnancy prevention strategies; 12.
- WBC & ALT at 2, 4, 8, 12 (up to 16) weeks after initiation that may influence dosing changes; Do Not give live virus vaccines
- 13. Dosing: 15mg/m2/week up to a maximum total dose of 25 mg subcutaneously, Continue for 12 16 weeks if labs normal
- Efficacy Monitoring: Assess if have achieved adequate clinical response to MTX after 12-16 weeks of use to further adjust dosing / continued use 14
- Adjunct Therapy / Other Treatment-Related Interventions / Education: supplemental folic acid 1 mg/day PO for GI side effects 15. **Infliximab** (also see the algorithm in Appendix #8 & Guideline)

16. Indications:

- induction of remission in children with moderate/severe CD who: a. · do not respond to or were intolerant of induction therapy with prednisone and 6MP/AZA, or
 - relapsed during their initial course of steroids and 6-MP / AZA, or
 - have failed immunomodulator therapies 6-MP / AZA and/or MTX, or
 - are steroid dependent/refractory defined as:
 - o received more than one course of steroids in one year, or
 - o not achieved remission after one month of prednisone alone, or

- o not tapered off prednisone after three months OR
- · Have any of the following: severe colitis requiring transfusion or severe small bowel disease or draining enterocutaneous or perinal fistulas
- b. *induction of remission* in children with moderate/severe UC who: are steroid dependent/refractory and/or
 - have failed immunomodulator therapies 6-MP / AZA
- c. maintenance therapy in children with moderate / severe CD / UC
- 17. Contraindications: Abscess, Signs & symptoms of infection, Hx of Tuberculosis, Histoplasmosis
- Safety Monitoring: Monitor Before Infliximab initiation: evaluate for tuberculosis and histoplasmosis WBC every 3 months while on Infliximab; If 10. suspected intra-abdominal abscess and/or fistulae- abdominal contrast (CT); If suspected perianal abscess and/or fistulae pelvic(MRI); if infection present, DELAY the infusion; Before & during each Infliximab infusion: monitor for acute infusion reactions & allergic and anaphylaxis precautions be taken; During Infliximab therapy and for a period of time following: maintain ongoing cancer surveillance & monitor delayed hypersensitivity reactions; Do Not give live virus vaccines
- 18. Dosing: 5mg/kg at initiation, 2, and 6 weeks Intravenously; Give all 3 doses, if labs normal
- 19. Efficacy Monitoring: Assess if have achieved adequate clinical response to Infliximab after 3 doses (6 weeks of use) to further adjust dosing / continued use
- 20. Adjunct Therapy / Other Treatment-Related Interventions / Education: Consider Prophylactic Pre-Infusion Meds: Benadryl Acetaminophen (standard dosing); educate patients and families regarding delayed reactions and contraindications for receiving an infusion

See complete Evidence-Based Care Guideline for details and supporting evidence. Adherence to recommendations is voluntary. Ultimate judgment regarding priority of any specific procedure must be made by the physician in light of the individual circumstances presented by the patient. Copyright © 2007 Cincinnati Children's Hospital Medical Center; all rights reserved.



Supplemental Figure 1C



Infliximab Treatment Algorithm Revision Date: 07/31/2009

